Table 3.

Time to Hemostasis at Vascular Access Site

	All Days	Non-Dosing Daysa			Day of Dosing
	Overallb (n = 34)	Placebob (n = 10)	AB002 1.5 µg/kg (n = 12)	AB002 3 µg/kg (n = 12)	Placebob (n = 10)	AB002 1.5 µg/kg (n = 12)	AB002 3 µg/kg (n = 12)
Assessments > 10 min (relative frequency)c	17/169 (10%)	3/40 (8%)	8/47d (17%)	2/48 (4%)	3/10 (30%)	1/12 (8%)	0/12 (0%)

^aAssessments performed on non-dosing days (days −7, −5, −2, 3) were combined.

^bTwo patients had chest catheters and were not assessed for time to hemostasis.

^cDefined as the number of events in which the time to hemostasis assessment was greater than 10 minutes divided by the total number of assessments per category and expressed as a percentage for comparison across treatment groups.

^dOne assessment was not performed because patient in the 1.5 µg/kg treatment group received hemodialysis off-site on day −2.